cas 1990505-77-5|| where to buy Methyl (S)-4-amino-5-(4-methylpiperazin-1-yl)-5-oxopentanoate dihydrochloride

Product Name:Methyl (S)-4-amino-5-(4-methylpiperazin-1-yl)-5-oxopentanoate dihydrochloride

IUPAC Name:methyl (4S)-4-amino-5-(4-methylpiperazin-1-yl)-5-oxopentanoate dihydrochloride

: CAS：1990505-77-5; Molecular Formula：C11H23Cl2N3O3; Purity：95%+

Packing Unit	Available Stock	Price($)	Quantity
CM336165-1g	in stock	țȺư

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1990505-77-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:1990505-77-5; Molecular Formula:C11H23Cl2N3O3; Melting Point:-; Smiles Code:N[C@@H](CCC(OC)=O)C(N1CCN(C)CC1)=O.[H]Cl.[H]Cl; Density:

: Catalog Number:CM336165; Molecular Weight:316.22; Boiling Point:; MDL No:; Storage:

: Piperazines; Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.

: Bomedemstat; Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.